Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research
Cost difficulties affect 54% of users regardless of insurance status
IV Nutrient Therapy: The clinic provides IV drips that offer a multitude of potential benefits, including energy boosts, detoxification, immune system enhancement, and illness prevention
5-8,10 Ultimately, obesity and T2D are associated with detrimental structural changes in bone, such as decreased trabecular bone connectivity and cortical bone thickness, increasing the risk of fractures and impairing healing
Semaglutide is an injection you take once a week
According to the ASMBS, more than 270,000 metabolic and bariatric procedures were performed in 2023, which represents only about 1% of those who meet eligibility requirements based on BMI
US$ 27.53
US$ 22.21
US$ 27.18
US$ 21.97
US$ 24.93
US$ 24.33
US$ 22.59
US$ 25.92
US$ 26.94
US$ 28.89
